Drugs / Immune Globulin Infusion 10% (Human)
Immune Globulin Infusion 10% (Human)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02549170 | Dec 2015 → Feb 2022 | chronic inflammatory demyelinating polyradiculoneuropathy | Baxalta now part of Shire | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immune Globulin Infusion 10% (Human) | “Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).” NCT02549170 ↗ |
| Modality | Protein / enzyme biologic | “Immune Globulin Infusion 10% (Human) (IGI, 10%)” NCT02549170 ↗ |
| Route | Subcutaneous | “HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human)” NCT02549170 ↗ |